JournalsHub
.online
Find My Journal
SL

S. Loibl

German Breast group DE

5
Publications
684
Citations
2
H-Index
1
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn +18 more
Annals of Oncology 2019
682
A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo) OA
S. Loibl, Andreas Schneeweiß, Nicole Burchardi, Jens‐Uwe Blohmer, Claus Hanusch +8 more
Annals of Oncology 2016
3

Publications

5 total

266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial

Guillermo Villacampa, Natalie Filmann, P.A. Fasching, J. Balmaña, Thomas Karn et al. - Annals of Oncology, 2024
Cited by 0 OpenAlex

Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- LOBSTER

Jens‐Uwe Blohmer, Maria Margarete Karsten, Carsten Denkert, Vesna Bjelic‐Radisic, Mattea Reinisch et al. - Senologie - Zeitschrift für Mammadiagnostik und -therapie, 2024
Cited by 0 OpenAlex

PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer

Vesna Bjelic‐Radisic, Elisabetta Munzone, M. Untch, C. Denkert, Nader Hirmas et al. - Senologie - Zeitschrift für Mammadiagnostik und -therapie, 2024
Cited by 0 OpenAlex

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn et al. - Annals of Oncology, 2019
Cited by 682 OpenAlex

A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo) PDF

S. Loibl, Andreas Schneeweiß, Nicole Burchardi, Jens‐Uwe Blohmer, Claus Hanusch et al. - Annals of Oncology, 2016
Cited by 3 OpenAlex

Research Topics

HER2/EGFR in Cancer Research (3) Cancer Immunotherapy and Biomarkers (2) Breast Cancer Treatment Studies (2) Estrogen and related hormone effects (2) Lung Cancer Treatments and Mutations (1)

Frequent Co-Authors

JE
Jens‐Uwe Blohmer
4 joint publications
JE
Jens Huober
3 joint publications
CL
Claus Hanusch
3 joint publications
KE
Kerstin Rhiem
3 joint publications
MI
Michael Untch
2 joint publications
NI
Nicole Burchardi
2 joint publications

Affiliations

Cardiovascular Center Bethanien
DE 2019 - 2019
German Breast group
DE 2024 - 2016

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now